Last reviewed · How we verify
Monad 2
At a glance
| Generic name | Monad 2 |
|---|---|
| Also known as | Halobetasol Propionate (HBP) |
| Sponsor | Citius Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids (PHASE2)
- Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis (PHASE2)
- Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris (PHASE2)
- Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis (PHASE1)
- An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monad 2 CI brief — competitive landscape report
- Monad 2 updates RSS · CI watch RSS
- Citius Pharmaceuticals, Inc. portfolio CI